Maravai Lifesciences Holdings

Maravai Lifesciences Holdings

MRVI· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -40.4% in FY2025

Bernd Brust is the CEO of Maravai Lifesciences Holdings and was paid $10.1M in FY2025 (Dec).

Pay$100 in the stock at the end of FY24 → $60
CEO pay is from each Maravai Lifesciences Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives7

See all
  1. 1Bernd BrustFY2025
  2. 2William E. Martin, IIIFY2025
  3. 3Raj AsarpotaFY2025
  4. 4Peter Leddy, PhDFY2025
  5. 5Kevin HerdeFY2025
  6. 6Kurt OreshackFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Maravai Lifesciences Holdings paid its 7 named executives $24.0M in total in FY2025 (Dec). CEO Bernd Brust was paid $10.1M of that.

Name
Bernd BrustChief Executive OfficerNot disclosedNot disclosed
William E. Martin, IIIFormer Chief Executive Officer
Raj AsarpotaChief Financial OfficerNot disclosedNot disclosed
Peter Leddy, PhDChief Administrative Officer
Kevin HerdeFormer Chief Financial Officer
Kurt OreshackSecretary and General CounselNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Maravai Lifesciences Holdings names 17 peer companies for pay. Pay versus performance data of Maravai Lifesciences Holdings for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • John DeFord, PhDDirector · 2 yr on the boardIndependentAudit, Compensation and Leadership Development (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Maravai Lifesciences Holdings Former CEO pay fell 40% to $3.8M. The stock fell 40% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Maravai Lifesciences Holdings Chief Administrative Officer pay fell 22% to $1.8M. The stock fell 40% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Maravai Lifesciences Holdings Former CFO pay fell 26% to $1.7M. The stock fell 40% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Maravai Lifesciences Holdings Former CEO pay rose 177% to $6.4M. The stock fell 17% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Maravai Lifesciences Holdings Chief Administrative Officer pay fell 16% to $2.4M. The stock fell 17% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Maravai Lifesciences Holdings Former CFO pay fell 16% to $2.3M. The stock fell 17% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Maravai Lifesciences Holdings Former President, Nucleic Acid Production pay fell 15% to $2.6M. The stock fell 17% in FY2024 (Dec).
    DEF 14A
  8. Board
    R. Andrew Eckert joined the board of Maravai Lifesciences Holdings. R. Andrew Eckert sits on no other public board.
    3
  9. Pay
    Maravai Lifesciences Holdings Former CEO pay fell 84% to $2.3M. The stock fell 54% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Maravai Lifesciences Holdings Chief Administrative Officer pay fell 28% to $2.8M. The stock fell 54% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Maravai Lifesciences Holdings Former CFO pay rose 60% to $2.8M. The stock fell 54% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Maravai Lifesciences Holdings Former CFO pay rose 107% to $1.7M. The stock fell 66% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Maravai Lifesciences Holdings Division head pay rose 42% to $2.3M. The stock fell 54% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Maravai Lifesciences Holdings Division head pay rose 89% to $1.6M. The stock fell 66% in FY2022 (Dec).
    DEF 14A
  15. Pay
    Maravai Lifesciences Holdings Chair pay rose 208% to $5.5M. The stock fell 66% in FY2022 (Dec).
    DEF 14A
  16. Board
    John DeFord, PhD joined the board of Maravai Lifesciences Holdings. John DeFord, PhD sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 18, 2025FY2024
Annual report10-KMar 18, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data